Amin Emad

Amin Emad

Auto-generated profile, based on publicly available information

Amin Emad

McGill University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Bioinformatics
Verified
Journal Article
Open access
PDF file
MKMohamed Reda El Khili
Mohamed Reda El Khili
SMSafyan Aman Memon
Safyan Aman Memon
AEAmin Emad
Amin Emad
Combination therapies have emerged as a treatment strategy for cancers to reduce the probability of drug resistance and to improve outcome. Large databases curating the results of many drug screening studies on preclinical cancer cell lines have been developed, capturing the synergistic and antagonistic effects of combination of drugs in different cell lines. However, due to the high cost of drug screening experiments and the sheer size of possible drug combinations, these databases are quite sparse. This necessitates the development of transductive computational models to accurately impute these missing values. Here, we developed MARSY, a deep learning multi-task model that incorporates information on gene expression profile of cancer cell lines, as well as the differential expression signature induced by each drug to predict drug-pair synergy scores. By utilizing two encoders to capture the interplay between the drug-pairs, as well as the drug-pairs and cell lines, and by adding auxiliary tasks in the predictor, MARSY learns latent embeddings that improve the prediction performance compared to state-of-the-art and traditional machine learning models. Using MARSY, we then predicted the synergy scores of 133,722 new drug-pair cell line combinations, which we have made available to the community as part of this study. Moreover, we validated various insights obtained from these novel predictions using independent studies, confirming the ability of MARSY in making accurate novel predictions. An implementation of the algorithms in Python and cleaned input datasets are provided in https://github.com/Emad-COMBINE-lab/MARSY. Online-only supplementary data are available at Bioinformatics online.

14 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYazdan Zinati
Yazdan Zinati
ATAbdulrahman Takiddeen
Abdulrahman Takiddeen
AEAmin Emad
Amin Emad
We introduce GRouNdGAN, a gene regulatory network (GRN)-guided reference-based causal implicit generative model for simulating single-cell RNA-seq data, in silico perturbation experiments, and benchmarking GRN inference methods. Through the imposition of a user-defined GRN in its architecture, GRouNdGAN simulates steady-state and transient-state single-cell datasets where genes are causally expressed under the control of their regulating transcription factors (TFs). Training on six experimental reference datasets, we show that our model captures non-linear TF-gene dependencies and preserves gene identities, cell trajectories, pseudo-time ordering, and technical and biological noise, with no user manipulation and only implicit parameterization. GRouNdGAN can synthesize cells under new conditions to perform in silico TF knockout experiments. Benchmarking various GRN inference algorithms reveals that GRouNdGAN effectively bridges the existing gap between simulated and biological data benchmarks of GRN inference algorithms, providing gold standard ground truth GRNs and realistic cells corresponding to the biological system of interest.

22 January 2020 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
EHEdward W Huang
Edward W Huang
ABAmeya Bhope
Ameya Bhope
JLJing Lim
Jing Lim
SSSaurabh Sinha
Saurabh Sinha
AEAmin Emad
Amin Emad
Prediction of clinical drug response (CDR) of cancer patients, based on their clinical and molecular profiles obtained prior to administration of the drug, can play a significant role in individualized medicine. Machine learning models have the potential to address this issue but training them requires data from a large number of patients treated with each drug, limiting their feasibility. While large databases of drug response and molecular profiles of preclinical in-vitro cancer cell lines (CCLs) exist for many drugs, it is unclear whether preclinical samples can be used to predict CDR of real patients. We designed a systematic approach to evaluate how well different algorithms, trained on gene expression and drug response of CCLs, can predict CDR of patients. Using data from two large databases, we evaluated various linear and non-linear algorithms, some of which utilized information on gene interactions. Then, we developed a new algorithm called TG-LASSO that explicitly integrates information on samples’ tissue of origin with gene expression profiles to improve prediction performance. Our results showed that regularized regression methods provide better prediction performance. However, including the network information or common methods of including information on the tissue of origin did not improve the results. On the other hand, TG-LASSO improved the predictions and distinguished resistant and sensitive patients for 7 out of 13 drugs. Additionally, TG-LASSO identified genes associated with the drug response, including known targets and pathways involved in the drugs’ mechanism of action. Moreover, genes identified by TG-LASSO for multiple drugs in a tissue were associated with patient survival. In summary, our analysis suggests that preclinical samples can be used to predict CDR of patients and identify biomarkers of drug sensitivity and survival. Cancer is among the leading causes of death globally and prediction of the drug response of patients to different treatments based on their clinical and molecular profiles can enable individualized cancer medicine. Machine learning algorithms have the potential to play a significant role in this task; however, these algorithms are designed based on the premise that a large number of labeled training samples are available, and these samples are accurate representations of the profiles of real tumors. However, due to ethical and technical reasons, it is not possible to screen humans for many drugs, significantly limiting the size of training data. To overcome this data scarcity problem, machine learning models can be trained using large databases of preclinical samples (e.g. cancer cell line cultures). However, due to the major differences between preclinical samples and real tumors, it is unclear how accurately such preclinical-to-clinical computational models can predict the clinical drug response of cancer patients. Here, first we systematically evaluate a variety of different linear and nonlinear machine learning algorithms for this particular task using two large databases of preclinical (GDSC) and tumor samples (TCGA). Then, we present a novel method called TG-LASSO that utilizes a new approach for explicitly incorporating the tissue of origin of samples in the prediction task. Our results show that TG-LASSO outperforms all other algorithms and can distinguish resistant and sensitive patients for the majority of the tested drugs. Follow-up analysis reveal that this method can also identify biomarkers of drug sensitivity in each cancer type.

30 June 2022 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
JSJoseph Szymborski
Joseph Szymborski
AEAmin Emad
Amin Emad
Motivation: Computational methods for the prediction of protein–protein interactions (PPIs), while important tools for researchers, are plagued by challenges in generalizing to unseen proteins. Datasets used for modelling protein–protein predictions are particularly predisposed to information leakage and sampling biases.Results: In this study, we introduce RAPPPID, a method for the Regularized Automatic Prediction of Protein–Protein Interactions using Deep Learning. RAPPPID is a twin Averaged Weight-Dropped Long Short-Term memory network which employs multiple regularization methods during training time to learn generalized weights. Testing on stringent interaction datasets composed of proteins not seen during training, RAPPPID outperforms state-of-the-art methods. Further experiments show that RAPPPID’s performance holds regardless of the particular proteins in the testing set and its performance is higher for experimentally supported edges. This study serves to demonstrate that appropriate regularization is an important component of overcoming the challenges of creating models for PPI prediction that generalize to unseen proteins. Additionally, as part of this study, we provide datasets corresponding to several data splits of various strictness, in order to facilitate assessment of PPI reconstruction methods by others in the future.Availability and implementation: Code and datasets are freely available at https://github.com/jszym/rapppid and Zenodo.org.Supplementary information: Supplementary data are available at Bioinformatics online.

1 June 2023 in Bioinformatics
Verified
Journal Article
Open access
PDF file
YLYihui Li
Yihui Li
DHDavid Earl Hostallero
David Earl Hostallero
AEAmin Emad
Amin Emad
Motivation: Interpretable deep learning (DL) models that can provide biological insights, in addition to accurate predictions, are of great interest to the biomedical community. Recently, interpretable DL models that incorporate signaling pathways have been proposed for drug response prediction (DRP). While these models improve interpretability, it is unclear whether this comes at the cost of less accurate DRPs, or a prediction improvement can also be obtained.Results: We comprehensively and systematically assessed four state-of-the-art interpretable DL models using three pathway collections to assess their ability in making accurate predictions on unseen samples from the same dataset, as well as their generalizability to an independent dataset. Our results showed that models that explicitly incorporate pathway information in the form of a latent layer perform worse compared to models that incorporate this information implicitly. However, in most evaluation setups, the best performance was achieved using a black-box multilayer perceptron, and the performance of a random forests baseline was comparable to those of the interpretable models. Replacing the signaling pathways with randomly generated pathways showed a comparable performance for the majority of the models. Finally, the performance of all models deteriorated when applied to an independent dataset. These results highlight the importance of systematic evaluation of newly proposed models using carefully selected baselines. We provide different evaluation setups and baseline models that can be used to achieve this goal.Availability and implementation: Implemented models and datasets are provided at https://doi.org/10.5281/zenodo.7787178 and https://doi.org/10.5281/zenodo.7101665, respectively.

8 June 2022 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
DHDavid Earl Hostallero
David Earl Hostallero
YLYihui Li
Yihui Li
AEAmin Emad
Amin Emad
The increasing number of publicly available databases containing drugs’ chemical structures, their response in cell lines, and molecular profiles of the cell lines has garnered attention to the problem of drug response prediction. However, many existing methods do not fully leverage the information that is shared among cell lines and drugs with similar structure. As such, drug similarities in terms of cell line responses and chemical structures could prove to be useful in forming drug representations to improve drug response prediction accuracy. We present two deep learning approaches, BiG-DRP and BiG-DRP+, for drug response prediction. Our models take advantage of the drugs’ chemical structure and the underlying relationships of drugs and cell lines through a bipartite graph and a heterogeneous graph convolutional network that incorporate sensitive and resistant cell line information in forming drug representations. Evaluation of our methods and other state-of-the-art models in different scenarios shows that incorporating this bipartite graph significantly improves the prediction performance. In addition, genes that contribute significantly to the performance of our models also point to important biological processes and signaling pathways. Analysis of predicted drug response of patients’ tumors using our model revealed important associations between mutations and drug sensitivity, illustrating the utility of our model in pharmacogenomics studies. An implementation of the algorithms in Python is provided in https://github.com/ddhostallero/BiG-DRP. Supplementary data are available at Bioinformatics online.